Table 4.
SILAC analysis of K562 cells to quantify phosphorylation site responsiveness to imatinib
| PSDB ID | pTyr site | Peptide | Control/treated |
|---|---|---|---|
| Peptides that are less abundant following imatinib treatment | |||
| Adaptor/scaffold | |||
| Abi-1 | 213 | TLEPVKPPTVPNDyMTSPAR | > 2 |
| CD2AP | 548 | DTCYSPKPSVyLSTPSSASK | > 2 |
| Gab1 | 406 | DASSQDCyDIPR | > 4 |
| Shc | 427 | ELFDDPSyVNVQNLDK | > 10 |
| Protein kinase | |||
| Abl | 115 | NGQGWVPSNyITPVNSLEK | > 10 |
| Abl | 393 | LMTGDTyTAHAGAK | > 20 |
| Abl | 393 | VADFGLSRLMTGDTyTAHAGAK | > 10 |
| Bcr | 177 | GHGQPGADAEKPFyVNVEFHHER | > 2 |
| Bcr | 177 | KGHGQPGADAEKPFyVNVEFHHER | > 10 |
| Bcr | 246 | SSESSCGVDGDyEDAELNPR | > 2 |
| Bcr | 591 | LASQLGVyR | > 5 |
| Bcr | 644 | NSLETLLyKPVDR | > 5 |
| ERK2 | 187 | VADPDHDHTGFLTEyVATR | > 2 |
| Lipid phosphatase | |||
| SHIP-2 | 986 | NSFNNPAYyVLEGVPHQLLPPEPPSPAR | > 20 |
| SHIP-2 | 1135 | TLSEVDyAPAGPAR | > 10 |
| Transcription factor | |||
| STAT5A | 694 | AVDGyVKPQIK | > 20 |
| Other | |||
| LIM | 142 | YTEFyHVPTHSDASK | > 2 |
| ZO2 | 1118 | IEIAQKHPDIyAVPIK | > 2 |
| Peptide intensities remaining unchanged following imatinib treatment | |||
| Protein kinase | |||
| Cdc2 | 15 | IEKIGEGTyGVVYK | 1.10* |
| Cdc2 | 15 | IGEGTyGVVYK | 1.04* |
| Cdc2 | 15 | IGEGTyGVVYKGR | 1.04* |
| DYRK1A | 321 | IYQyIQSR | 1.04* |
| GSK3-β | 216 | GEPNVSyICSR | 1.22* |
| HIPK1 | 352 | AVCSTyLQSR | 1.03* |
| p-38-α | 182 | HTDDEMTGyVATR | 1.61 |
| PRP4 | 849 | LCDFGSASHVADNDITPyLVSR | 1.14* |
| Other | |||
| eEF1A-1 | 29 | STTTGHLIyK | 1.33 |
| Peptides without definitive quantification | |||
| Adaptor/scaffold | |||
| Cbl | 674 | IKPSSSANAIySLAARPLPVPK | ND |
| Other | |||
| Calmodulin | 100 | VFDKDGNGyISAAELR | ND |
ND indicates not determined.
*
Cdc2, DYRK1A, GSK3-beta, HIPK1 and PRP4 were not expected to be drug sensitive from the signature data, and can be viewed as a representative ratio of control/treated.